StockData
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. (ACRV) stock

ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $61.28MP/E –Yield –

Acrivon Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Acrivon Therapeutics's total assets was $99.09M at Jun 30, 2026. For fiscal 2025 it was $129.72M, down 34.0% from the year before. The highest annual figure on record is $196.59M in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$129.72M-34.0%
FY2024Dec 31, 2024$196.59M+42.2%
FY2023Dec 31, 2023$138.27M-23.7%
FY2022Dec 31, 2022$181.23M+70.0%
FY2021Dec 31, 2021$106.59M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$99.09M-37.5%
Q1 FY2026Mar 31, 2026$107.83M-38.9%
Q4 FY2025Dec 31, 2025$129.72M-34.0%
Q3 FY2025Sep 30, 2025$145.30M-32.3%
Q2 FY2025Jun 30, 2025$158.58M-31.2%
Q1 FY2025Mar 31, 2025$176.35M+46.3%
Q4 FY2024Dec 31, 2024$196.59M+42.2%
Q3 FY2024Sep 30, 2024$214.68M+42.1%
Q2 FY2024Jun 30, 2024$230.59M+44.1%
Q1 FY2024Mar 31, 2024$120.52M-29.2%
Q4 FY2023Dec 31, 2023$138.27M-23.7%
Q3 FY2023Sep 30, 2023$151.09M+72.3%
Q2 FY2023Jun 30, 2023$160.05M+50.2%
Q1 FY2023Mar 31, 2023$170.20M–
Q4 FY2022Dec 31, 2022$181.23M–
Q3 FY2022Sep 30, 2022$87.71M–
Q4 FY2021Dec 31, 2021$106.59M–

More Acrivon Therapeutics figures

See a number that looks wrong?